Insider trade

Tuhura Biosciences, Inc. (HURA): Director received 156K units

Alan List, Director at Tuhura Biosciences, Inc., reported a grant / award of 156K units.

156K
Derivative units
Traded
Feb 12, 2026
Filed
Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 29, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On January 29, 2026, TuHURA Biosciences, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 35 consecutive business days as of January 28, 2026, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price requirement for…”

What came next

  1. Apr 1, 2026Company filing · Form 8-K · ResultsReported its results
  2. Apr 2, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On April 2, 2026, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) approved annual performance bonuses for 2025 for Dr. James Bianco, the Company’s President and Chief Executive Officer, and Dan Dearborn, the Company’s Chief Financial Officer, in the amount of $490,536 for Dr. Bianco and $163,393 for Mr. Dearborn.”
  3. Apr 21, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 2 more items)
  4. May 15, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
  5. May 26, 2026Company filing · Form 8-K · New debtTook on new debt or obligations
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Tuhura Biosciences, Inc.

OQRO holds no insider, Congress, fund or contract record for Tuhura Biosciences, Inc. dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HURA page.

How this filing works

Explore the data

Common questions

Which Tuhura Biosciences, Inc. (HURA) insider traded, and how much?

Alan List, Director at Tuhura Biosciences, Inc., reported a grant / award of 156K units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Feb 12, 2026. Filed: Feb 17, 2026. That is 5 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean HURA stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Tuhura Biosciences, Inc.

Everything OQRO holds on this company is on its HURA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data